fluticasone/umeclidinium/vilanterol (Trelegy Ellipta)
Jump to navigation
Jump to search
Indications
- maintenance treatment of COPD with asthma or eosinophilia
- maintenance treatment of asthma
* no improvement in mortality[2]
* safe for patients with cardiovascular disease[2]
* predominantly benefits patients with elevated blood eosinophil count (> 300 x 10E6/L)[1]
Contraindications
- not FDA-approved to treat asthma in children or adolescents or to treat acute bronchospasm[2]
Dosage
- once a day dry powder
Laboratory
- complete blood count
- eosinophil count: > 300 x 10E6/L[1]
Mechanism of action
- combination of inhaled glucocorticoid (fluticasone) with long-acting beta-2 adrenergic receptor agonist (vilanterol) & muscarinic antagonist
More general terms
References
- ↑ 1.0 1.1 1.2 Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med 2020 Aug 4; 173:ITC17 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32745458
Agusti A, Celli BR, Criner GJ et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary. Am J Respir Crit Care Med. 2023 Apr 1;207(7):819-837. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36856433 PMCID: PMC10111975 Free PMC article https://www.atsjournals.org/doi/10.1164/rccm.202301-0106PP - ↑ 2.0 2.1 2.2 2.3 Highlights of Prescribing Information Trelegy Ellipta (fluticasone furoate/umeclidinium/vilantero https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF